briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Medication Overview

For people with relapsing multiple sclerosis (RMS)

Scan this QR code or visit briumvi.com to find out more about BRIUMVI.

What is BRIUMVI?

BRIUMVI is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is not known if BRIUMVI is safe or effective in children.

Important Safety Information

Who should not receive BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

Please see Important Safety Information and full Prescribing Information.

Welcome to the BRIUMVI Medication Overview

The only B-cell therapy for RMS designed to be administered in 1-hour, twice per year.[a]

Thank you for considering BRIUMVI. This brochure will help to inform you about BRIUMVI, as well as guide you through our inclusive support services. You can also go to **briumvi.com** for more information.

We recommend taking time to discuss the following content with your healthcare provider and whether BRIUMVI is right for you.

[a]Following the starting dose.

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Let's begin

In this brochure, you will

- Learn more about BRIUMVI
- Find out how BRIUMVI is administered
- Discover educational resources for BRIUMVI
- Get to know more about patient support and how to access BRIUMVI
- Understand how to start a discussion with your healthcare provider

We invite you to carefully review the following information in this brochure and don't hesitate to talk to your healthcare provider about any questions you may have.

Tell me about BRIUMVI

What is BRIUMVI?

BRIUMVI is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is not known if BRIUMVI is safe or effective in children.

How often will I receive BRIUMVI?

You will be given BRIUMVI as a 1-hour intravenous (IV) infusion every 6 months (24 weeks) following the starting dose. For more details about the infusion process, see "How will I be given BRIUMVI?" on **page 7**.

What are the ingredients in BRIUMVI?

Active ingredient: ublituximab-xiiy

Inactive ingredients: hydrochloric acid, polysorbate 80, sodium chloride, sodium citrate, water for injection, USP.

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Who do I talk to if I have more questions?

It is recommended that you have a conversation with your healthcare provider about BRIUMVI after reviewing this information. They can help answer more personalized questions about whether BRIUMVI is right for you, as RMS may affect each person differently.

Find more info about BRIUMVI at briumvi.com.
You can also call 1-833-BRIUMVI (1-833-274-8684).

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Clinical studies of BRIUMVI

Efficacy of BRIUMVI

- In two 2-year studies, BRIUMVI was tested alongside another treatment (teriflunomide) for RMS in 1,094 patients
- BRIUMVI was proven superior to teriflunomide at reducing relapses and significantly reduced brain lesions on magnetic resonance imaging (MRI)

Relevant safety information

The most common side effects of BRIUMVI include infusion reactions (48%), upper and lower respiratory tract infections (54%), herpes infections (6%), extremity pain (6%), insomnia (6%), and fatigue (5%).

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

How will I be given BRIUMVI?

BRIUMVI is given through a needle placed in your vein in your arm (IV infusion).



- Your first dose of BRIUMVI will last about 4 hours
- Your second dose will be given 2 weeks after your first dose—this infusion will last about 1 hour
- Your next doses of BRIUMVI will be given as **1 infusion every 6 months (24 weeks)**. These infusions will also **last about 1 hour**

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Tell me about premedication for BRIUMVI



Before treatment with BRIUMVI, you will receive a corticosteroid and an antihistamine to help reduce the risk of infusion reactions by making them less frequent and less severe. You may also receive other medicines to help reduce the risk of an infusion reaction.

Who should not be given BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Before receiving BRIUMVI, what should my healthcare provider know about me?

Tell your healthcare provider about all your medical conditions, including if you

- Have or think you have an infection
- Take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection
- Have ever had hepatitis B or are a carrier of HBV
- Have had a recent vaccination or are scheduled to receive any vaccinations
  - **You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with BRIUMVI.** You **should not receive** 'live' or 'live-attenuated' vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened
  - **When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with BRIUMVI.** If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider
  - If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby's healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated
- Are pregnant, think that you might be pregnant, or plan to become pregnant. BRIUMVI may harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time
- Are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

What is the most important safety information about BRIUMVI?

BRIUMVI can cause serious side effects, including

Infusion reactions

Infusion reactions are among the most common side effects of BRIUMVI. Infusion reactions can be serious and may require you to be hospitalized. You will be monitored for 1 hour after the first 2 infusions. Monitoring after additional infusions may not be needed if there are no infusion reactions and/or hypersensitivity seen by your healthcare provider. Tell your healthcare provider if you get any of these symptoms:

- Fever
- Chills
- Headache
- Flu-like symptoms
- Fast heartbeat
- Hives
- Itchy skin
- Dizziness
- Feeling faint
- Swelling of the tongue or throat
- Trouble breathing
- Wheezing
- Nausea
- Abdominal pain
- Throat irritation
- Redness of the face or skin

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

What is the most important safety information about BRIUMVI? (cont'd)

These infusion reactions can happen over 24 hours after your infusion.

It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed on the previous page after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

Call your healthcare provider for medical advice about side effects. You may report side effects to **TG Therapeutics** at **1-877-848-9462** or **the US Food and Drug Administration (FDA)** at **1-800-FDA-1088**.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Possible side effects of BRIUMVI

Infections

- Infections are a common side effect, and upper respiratory tract infections are among the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone
  - **Hepatitis B virus (HBV) reactivation:** Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for HBV infection. If you have ever had an HBV infection, the HBV may become active again during or after treatment with BRIUMVI. HBV becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for HBV reactivation during treatment and after you stop receiving BRIUMVI
  - **Weakened immune system:** BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections
  - **Progressive multifocal leukoencephalopathy (PML):** PML may happen with BRIUMVI. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes

Low immunoglobulin levels

- BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

A flexible program designed to support the treatment journey in a way that works best for you

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV patient support

Dedicated case manager

Who will serve as your single point of contact and support you throughout your treatment journey

Insurance support

Information to help you understand your insurance coverage and locate a nearby infusion center that accepts your insurance

Financial assistance

Options that may help assist you with the cost of BRIUMVI, including BRIUMVI Copay Assistance where eligible patients may pay as little as $0 copay per BRIUMVI treatment as well as help to cover infusion-related costs[a]

[a]For commercially insured patients only. Other eligibility requirements apply. Click **here** for full Terms and Conditions.

1-833-BRIUMVI (1-833-274-8684)

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Discover advocacy groups*

A large network of advocacy organizations is ready to help you navigate life with MS. Explore the websites below to access helpful resources, services, and support.

MyMSAA.org

Offers a variety of support services, such as a toll-free helpline with experienced specialists, educational resources, and their MRI Access Program. Visit the site listed above or call **1-800-532-7667**.

nationalMSsociety.org

Serves the MS community by offering different platforms to connect, such as educational programs and local support groups, while also sharing information on all things MS. Visit the site listed above or call **1-800-344-4867**.

CanDo-MS.org

Delivers health and wellness education programs to help families living with MS. Visit the site listed above or call **1-800-367-3101**.

MSViews.org

MS Views and News keeps people affected by MS up to date with free educational information, resources, and the latest research, plus live and online educational programs. Visit the site listed above or call **1-888-871-1664**.

MSFocus.org

MS Focus provides services that address the critical needs of people with MS and their families. The organization's primary focus is on helping individuals with MS to access what they need to maintain their health and well-being. MS Focus charges no membership fees and all services are free to people with MS and their families. Visit the site listed above or call **1-888-673-6287**.

*TG Therapeutics is not affiliated with these independent organizations and does not recommend one organization over the other. Please note that the content of these websites is the sole responsibility of the website providers. TG Therapeutics does not control, review, edit, or influence this third-party content in any manner and makes no warranty as to the services offered by any organization listed here.

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Caregiver support organizations*

Get to know an organization that aids friends or loved ones who support those in the MS community.

Caregiving.com

For more than 25 years, Caregiving.com has been the premier online community for family caregivers. Created and run by current, former, and future caregivers, they are a digital care community connecting caregivers from all backgrounds to exclusive content and local resources to help them succeed in their care journeys. They deliver practical caregiving tips, tools, and access to relevant resources to help caregivers care for themselves and their loved ones at every stage in the caregiving journey.

*TG Therapeutics is not affiliated with these independent organizations and does not recommend one organization over the other. Please note that the content of these websites is the sole responsibility of the website providers. TG Therapeutics does not control, review, edit, or influence this third-party content in any manner and makes no warranty as to the services offered by any organization listed here.

Contact us

Visit **briumvipatientsupport.com** to learn more.

Call **1-833-BRIUMVI** (1-833-274-8684) to speak with a **dedicated BRIUMVI patient support case manager**.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Important Safety Information

Who should not receive BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

What is the most important information I should know about BRIUMVI?

BRIUMVI can cause serious side effects, including:

- **Infusion reactions:** Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:
  - fever
  - chills
  - headache
  - flu-like symptoms
  - fast heartbeat
  - hives
  - itchy skin
  - dizziness
  - feeling faint
  - swelling of tongue or throat
  - trouble breathing
  - wheezing
  - nausea
  - abdominal pain
  - throat irritation
  - redness of the face or skin

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

- **Infection:**
  - Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

Important Safety Information (cont'd)

- **Hepatitis B virus (HBV) reactivation:** Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
- **Weakened immune system:** BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
- **Progressive Multifocal Leukoencephalopathy (PML):** PML may happen with BRIUMVI. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
- **Low immunoglobulins:** BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection.
- take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have had a recent vaccination or are scheduled to receive any vaccinations.
  - **You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with BRIUMVI.** You **should not receive** 'live' or 'live-attenuated' vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.

Please see Important Safety Information and full Prescribing Information.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

Important Safety Information (cont'd)

  - **When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with BRIUMVI.** If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
  - If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby's healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
- are pregnant, think that you might be pregnant, or plan to become pregnant. BRIUMVI may harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
- are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BRIUMVI?

The most common side effects of BRIUMVI include:

- Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at **1-800-FDA-1088**. You may also report side effects to TG Therapeutics at **1-877-TGTXINC (1-877-848-9462)**.

For more important information, go to **www.briumvi.com** or call **1-833-BRIUMVI (1-833-274-8684)**.

Please see Important Safety Information and full Prescribing Information.

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV

For more information go to briumvi.com
or call 1-833-BRIUMVI (1-833-274-8684)

TG Therapeutics

briumvi®
ublituximab-xiiy 150 mg/6 mL injection for IV